Cefaly transcutaneous electrical nerve stimulation (TENS) device provided relief to 81% of migraine sufferers who used it, according to results of a clinical study published in The Journal of Headache and Pain.
Researchers from the Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences in Naples identified 24 migraineurs who frequently suffered episodic migraine without aura. After using the Cefaly device for 20 minutes a day for at least 2/3 of the required 60-day consecutive treatment period, patients saw a high level of efficacy. This was the first study to demonstrate that the headache pain intensity during a migraine attack was significantly reduced after using the Cefaly device whereas earlier studies only addressed migraine prevention. This test cohort matched the category of patients in the study (n=2,313) that supported the Food and Drug Administration (FDA)’s approval in March 2014.
Cefaly is a non-drug TENS device that uses small electrical impulses to stimulate the trigeminal nerve and reduce the frequency and intensity of migraines. Cefaly is available through a prescription only.
1. Antonio, R et al. J Headache Pain. 2015 doi: 10.1186/s10194-015-0551-3.
This article originally appeared on MPR